US/UK/Canada

Share

Contacts

  • Catharina Johansson

    CFO, IR & Communications


    Medicon Village 223 81 Lund Sweden
    +46 (0)46-275 62 21
    http://www.abliva.com
  • Abliva
    +46 (0)46 275 62 20
    • Pick a time period -
    Tags ( Active)

    Save the date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019

    Lund, 20 August 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company will host a Capital Markets Day in Stockholm on 9 October, 2019, for investors, analysts and media.Presentations will be made by members of NeuroVive's management and board as well as by external authorities in genetic mitochondrial diseases. The program includes an overview of the company's operations and strategy with deeper descriptions of the key projects, the company's external collaborations and the regulatory path towards market approval. Furthermore, an overview

    NeuroVive’s IND for clinical development of NeuroSTAT approved by FDA

    Lund, Sweden,10 May 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive’s IND (Investigational New Drug) application, enabling clinical studies in the US with the company’s drug candidate NeuroSTAT in development for treatment of moderate to severe traumatic brain injury, TBI.In the US, an FDA approved IND application is needed in order for not yet marketed investigational drugs to be used in clinical studies. The application has to contain detailed information about pharmacology and

    NeuroVive Pharmaceutical AB (publ): Report from AGM

    NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) yesterday, 28 April 2016. A summary of the resolutions follows. All resolutions were passed with the required majority.Adoption of Income Statement, Balance Sheet, Consolidated Income Statement, Consolidated Balance Sheet and appropriation of profit and dividendThe Meeting resolved to adopt the presented Income Statement and Balance Sheet, and the Consolidated Income Statement and Consolidated Balance Sheet. The Meeting also resolved to appropriate the company’s profit or loss in accordance with the Board of

    NeuroVive’s R&D Team to Present Research Progress at Mitochondrial Medicine Conference

    NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, will present important research findings together with researchers at Lund University in three scientific poster presentations at the conference entitled “Mitochondrial Medicine: Developing New Treatments for Mitochondrial Disease” being held 4-6 May 2016 in Cambridge, United Kingdom.The three scientific contributions submitted by the NeuroVive and Lund University research team have been accepted for poster presentation at the upcoming mitochondrial conference where global mitochondrial experts will be gathered. The

    NeuroVive starts preclinical TBI program in collaboration with PENN

    NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, announces the start of the first study in the preclinical program in traumatic brain injury (TBI) which is being done in collaboration with the University of Pennsylvania (PENN).The TBI preclinical research program includes 3 different studies evaluating the protective effect of NeuroSTAT® in a TBI experimental model. TBI is an important unsolved problem in the medical field: nerve cell protection following moderate to severe brain trauma. There currently exist no approved treatments for this medical problem

    NeuroVive: large shareholder to participate in the rights issue

    NeuroVive Pharmaceutical AB (publ) announces that Baulos Capital Belgium SA, one of the largest shareholders, intends to participate in the upcoming rights issue.Fredrik Olsson (Baulos Capital) has informed the NeuroVive board of Baulos Capital's intention to subscribe for shares in NeuroVive's rights issue with a subscription period between April 18 - May 2, 2016. The commitment means a subscription of at least 75,000 units to the rights issue subscription price of 42 SEK, corresponding to 3.15 MSEK. Baulos Capital has also agreed to sell off unexercised warrants outside of the stock

    NeuroVive strengthens its organization with the recruitment of Cecilia Hofvander as IR and Communications Director

    NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that it has recruited Cecilia Hofvander as Investor Relations and Communications Director effective from 1 June 2016 in order to strengthen the company’s communication resources.Cecilia Hofvander joins NeuroVive from Active Biotech AB where she has worked for 15 years, the last eight as Assistant Director Investor Relations & Business Development. She holds a B.Sc in Chemistry and Molecular Biology from Lund University and has completed the Communication Executive Program at the Stockholm School of Economics.

    Notice of extraordinary general meeting in NeuroVive Pharmaceutical AB (publ)

    The shareholders in NeuroVive Pharmaceutical AB (publ) reg. no. 556595-6538  (the “Company”) are hereby convened to the extraordinary general meeting, held at 10.00 a.m. on Thursday, 31 March 2016 at Grand Hotel Lund, Bantorget 1 in Lund, Sweden, with admission for registration from 9.30 a.m.Entitlement to participate and notification Shareholders who wish to participate at the extraordinary general meeting must: · be included in the share register maintained by Euroclear Sweden AB on Wednesday 23 March 2016, and · notify the Company in writing by no later than Wednesday 23 March

    NeuroVive resolves on rights issue totaling approximately SEK 94.4 million for continued development of the project portfolio

    On 28 February 2016, The Board of Directors of NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or ”the Company”) decided to carry out a new issue of shares and warrants (units) with preferential rights for existing shareholders (the “New Issue”). The resolution is subject to approval by the forthcoming Extraordinary General Meeting. Upon full subscription of the New Issue, the Company will raise approximately SEK 94.4 m before issue expenses. Full exercise of the warrants will raise at least a further SEK 32.6 million for the Company. The proceeds from the New Issue will be used for NeuroVive’

    NeuroVive Pharmaceutical AB (publ) - amendment number of shares and votes

    Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of share issue in kind conducted by NeuroVive Pharmaceutical AB (publ) (“NeuroVive”), as resolved by the Board of Directors on 13 January 2016 with the authorization by the annual general meeting on 30 March 2015, the number of shares and votes of NeuroVive registered with the Swedish Companies Registration Office have increased by 738,533. Accordingly, the total number of shares and votes in NeuroVive is 31,473,685.About NeuroViveNeuroVive

    Board Selects New CEO Erik Kinnman to Lead NeuroVive

    NeuroVive Pharmaceutical AB (publ) board of directors is pleased to announce that it has selected Erik Kinnman as NeuroVive’s Chief Executive Officer (CEO). Erik Kinnman will assume the new role on the 14th March 2016, leaving Chief Medical Officer (CMO) and Chief Operating Officer (COO) roles within his own consultancy business.Erik Kinnman is a seasoned life science executive with broad experience and understanding from the industry across a variety of businesses and functions. He has held a number of senior leadership positions in biopharmaceutical companies such as AstraZeneca and Sobi.

    NeuroVive buys stake in Isomerase Therapeutics

    Lund, Sweden, 14 January 2016 – NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces the partial acquisition of British company Isomerase Therapeutics (“Isomerase”) with the overall goal to strengthen the partnership and accelerate NeuroVive’s research and development (R&D) program.The acquisition aims to further enhance the collaboration and to ensure that NeuroVive’s projects remain a key priority for Isomerase. Furthermore, the partnership will support the discovery of new compounds, based on the additional expertise Isomerase brings to the partnership. This

    NeuroVive Presents Findings Targeting Complex I Deficiency at World Mitochondria Congress

    Lund, Sweden, 2 November 2015 – NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces the presentation of preclinical data from its Complex I deficiency discovery program at the 6th World Congress on Targeting Mitochondria in Berlin, Germany.NeuroVive’s Complex I Deficiency discovery program, also known as NVP015, is focused on the generation of novel drug candidates that target mitochondrial energy regulation in a number of mitochondrial disorders associated with complex I deficiency such as Leigh Syndrome. The research presented last week focuses on the role

    Annual General Meeting 2016 and Nomination Committee

    The Annual General Meeting of NeuroVive Pharmaceutical AB (publ) will be held on 28 April 2016 at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden.Shareholders are entitled to have a matter addressed by the Annual General Meeting as long as their request has been received by the Board of Directors by 10 March 2016. The Board of Directors can be contacted by email at: styrelsen@neurovive.com, or by mail at: NeuroVive Pharmaceutical AB, FAO: Greg Batcheller, Medicon Village, 223 81 Lund, Sweden. The AGM on 30 Mars 2015 resolved that NeuroVive shall have a Nomination Committee

    NeuroVive announces departure of CEO and appointment of Jan Nilsson as interim CEO

    NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces a change in leadership of the company.  Effective today, Mikael Brönnegård will no longer serve as Chief Executive Officer. The Board is pleased to announce that NeuroVive’s COO Jan Nilsson, who has extensive experience at senior levels within international pharmaceutical companies, will take over as interim CEO.The recruitment process to find a successor has begun and the company’s COO Jan Nilsson will head up the company in the role of interim CEO in the period until a new CEO is appointed by the Board of

    NeuroVive refocuses CicloMulsion development – discontinues acute myocardial infarction indication

    CicloMulsion® development to continue in acute kidney injury and increased focus on development of other drug candidates. Shareholder information meeting to be held on 10th September 2015 in Lund, Sweden to present and discuss the NeuroVive portfolio. NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces it will not pursue development of CicloMulsion® in the indication of acute myocardial infarction (AMI). The company will now place strategic focus on progressing the research and development activities of CicloMulsion® in acute kidney injury, the development of its

    NeuroVive: Interim Report 1 Jan. 2015 to 31 Jun. 2015

    Negative top-line result of phase III study and continued progress in other clinical projectsSecond Quarter (1 Apr. 2015 – 30 Jun. 2015) · Net revenues were SEK 2,502,000 (0) and other operating income was SEK 377,000 (1,128,000). · Loss before tax was SEK -15,216,000 (-13,690,000). · Earnings per share* were SEK -0.54 (-0.69). · Diluted earnings per share** were SEK -0.54 (-0.69). Six Months (1 Jan. 2015 – 30 Jun. 2015) · Net revenues were SEK 2,502,000 (0) and other operating income was SEK 426,000 (1,171,000). · Loss before tax was SEK -29,487,000 (-23,567,000).

    NeuroVive share upgraded on OTC market in US

    NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company’s share has been upgraded from trading on the OTC Grey Market to OTC Pink in the US. The upgrade implies increased accessibility and transparency, and improves the potential to attract interest from US investors. This is in line with the company’s strategy to increase its presence in the US, the world’s largest pharmaceuticals market.Since March 2014, US investors have been able to trade electronically in the NeuroVive share in USD on the OTC Grey Market without requiring a Swedish broker

    Topline result of Phase III study of CicloMulsion® in acute myocardial infarction expected this quarter

    NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, expects to announce the topline result of the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart attack known as ST-segment elevation acute myocardial infarction (STEMI) this quarter due to an earlier than previously expected database lock. The final results of the analysis of the 12-month data are expected in the third quarter 2015.The topline result will provide baseline information on whether the primary endpoint has been met or not. This result will not contain specific data concerning

    NeuroVive: Interim report 1 Jan. 2015 till 31 Mar. 2015

    Capital raising characterizes NeuroVive´s first quarterFirst Quarter (1 Jan. 2015 – 31 Mar. 2015) · Net revenues were SEK 0 (0) and other operating income was SEK 49,000 (43,000). · Loss before tax was SEK -14,271,000 (-9,877,000). · Earnings per share* were SEK -0.50 (-0.39). · Diluted earnings per share** were SEK -0.50 (-0.39). * Profit/loss for the period divided by the average number of shares before dilution at the end of the period. **Profit/loss for the period divided by the average number of shares after dilution at the end of the period. Business highlights

    NeuroVive announces the intention to raise additional capital through a private placement

    NeuroVive Pharmaceutical AB (publ) (”NeuroVive” or the “Company”, OMX:NVP) today announces that the Company intends to raise new equity through a private placement directed towards qualified institutional investors. The Company intends to effect the private placement at a share volume and a price per share to be determined through an accelerated bookbuilding process. The Board of Directors will disapply the preferential subscription rights of existing shareholders in connection with the intended capital increase, which will take place within the limits of the authorization from the Annual

    Published data indicates protective effect of cyclosporine in patients with stroke

    The results of a clinical phase II study indicating that cyclosporine counteracts brain injury in a subset of stroke patients undergoing thrombolysis has been published in an article co-authored by one of NeuroVive’s research partners, professor Michel Ovize of Hospices Civils de Lyon (HCL).The French phase II study investigated the neuroprotective effect of cyclosporine, the active substance in NeuroVive’s product NeuroSTAT®, in 127 stroke patients who also received thrombolysis treatment (to reinstate the occluded blood flow) in the period 2009-2013. For all patients included in the study,

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe